Blocking NNMT activity has been shown in research settings to influence body composition, leading to reduced adipocyte size, alterations in fat mass, and measurable changes in plasma biomarkers such as glucose and cholesterol
The information provided here is based on animal research extrapolation and anecdotal reports from researchers and enthusiasts in the community
Peptides were well tolerated, with minimal adverse events.[3] Some peptide formulations predominantly oral and a smaller number of topical produce modest improvements in some parameters
Routine B12 monitoring is not mandated for tirzepatide, but baseline and periodic testing should be considered for high-risk patients, including those over 65, on concurrent metformin, with gastrointestinal disorders, or experiencing symptoms such as fatigue, neuropathy, or cognitive changes